NCT00264290

Valganciclovir to Reduce T Cell Activation in HIV Infection

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: University of California, San Francisco · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether treatment with valganciclovir decreases T cell activation levels among HIV-infected patients with asymptomatic cytomegalovirus (CMV) co-infection, potentially improving immune responses to antiretroviral therapy.

Conditions

• HIV Infections
• Cytomegalovirus Infections

Interventions

Type	Name	Description
DRUG	Valganciclovir	900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone.
DRUG	Placebo	Placebo designed to resemble Valganciclovir

Timeline

• Start date: 2006-08-01
• Primary completion: 2008-10-01
• Completion: 2008-11-01
• First posted: 2005-12-12
• Last updated: 2020-07-31
• Results posted: 2013-11-08

Locations

1 site across 1 country: United States